A Deep Dive Into The $100 Million Expansion Of A Sterile Fill/Finish Manufacturing Facility

As pharmaceutical and biotech companies evolve to offer an increasing number of complex therapeutics and additional drug delivery systems, manufacturing partners must also evolve to meet customer needs and deliver treatments to patients in the safest, most effective way possible.

Baxter BioPharma Solutions’ approximately $100 million expansion of its sterile fill/finish manufacturing facility in Halle/Westfalen, Germany adds state-of-the-art equipment for the filling of vials and pre-filled syringes, allowing Baxter to offer clients pre-filled syringe manufacturing capacity out of Europe for the first time. Both manufacturing lines will be set up to offer a wide range of flexibility to meet the customers' demands from both a capability and capacity standpoint. Learn how a manufacturing partner committed to continually investing in support for its customers is best suited to meet the demands of a dynamic marketplace.